Study summary

A weekly injection blocking two B-cell signals doubled response rates

Telitacicept phase 3 · 335 people, phase 3 · Published October 2025, New England Journal of Medicine

34.5percentage points more responders than placebo

What was tested

Telitacicept, which blocks both BLyS and APRIL (two signals that keep antibody-making B cells alive), against placebo, for active lupus, in China.

What they found

Responders on telitacicept outnumbered placebo by 34.5 percentage points (about 67% vs 33%).

What it means

Strong result, but from a single country; global trials are needed for approval elsewhere.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.